May. 12 at 8:39 PM
$RXRX
H2 will be so important …
The bull case is still alive because:
* REC-4881 has proof-of-concept and FDA path discussions.
* REC-1245 is platform-derived and has early clean safety/PK/PD.
* REC-4539 shows chemistry/design capability.
* Roche/Sanofi partnerships are still validation.
* State Street, Vanguard, ARK, BlackRock are not gone.
* Short interest is huge, so any real catalyst can move fast.
* Cash runway gives them time into early 2028.
The bear case is also real:
* No approved drug.
* Revenue is tiny/lumpy.
* Burn is high.
* Share count is huge.
* ATM overhang scares buyers.
* Good articles and conferences are not enough.
* Market wants data, not narrative.
